MicroPort NeuroTech Limited (2172.HK)

HKD 8.88

(-2.31%)

Market Cap (In HKD)

5.12 Billion

Revenue (In HKD)

665.62 Million

Net Income (In HKD)

145.54 Million

Avg. Volume

1.15 Million

Currency
HKD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
6.21-12.88
PE
-
EPS
-
Beta Value
-0.28
ISIN
KYG6083E1098
CUSIP
-
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Medical - Devices
CEO
Mr. Zhiyong Xie
Employee Count
-
Website
https://www.medneurotech.com
Ipo Date
2022-07-15
Details
MicroPort NeuroTech Limited engages in the research and development, production, and sale of neuro-interventional medical devices in the People's Republic of China and internationally. It offers NUMEN, a coil embolization system; NUMEN FR, a coil detachment system; Tubridge, a flow-diverting stent; Willis, an intracranial stent graft system; and Rebridge, an intracranial visualized stent for use in the treatment of hemorrhagic stroke. The company also provides APOLLO, an intracranial arterial stent system to treat intracranial atherosclerotic disease; and Bridge, a rapamycin target eluting vertebral artery stent system to treat cerebral atherosclerotic stenosis. In addition, it offers Neurohawk, a stent thrombectomy device; Tigertriever, an adjustable stent retriever for use in the treatment of acute ischemic stroke. The company was founded in 2004 and is headquartered in Shanghai, the People's Republic of China.